Giulia Chiesa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/264461/publications.pdf Version: 2024-02-01



CILILIA CHIESA

#	Article	IF	CITATIONS
1	Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations Journal of Clinical Investigation, 1992, 90, 52-60.	8.2	838
2	Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature, 1992, 360, 670-672.	27.8	279
3	Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a) Journal of Clinical Investigation, 1993, 92, 3029-3037.	8.2	227
4	Recombinant Apolipoprotein A-IMilanoInfusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks. Circulation Research, 2002, 90, 974-980.	4.5	192
5	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 925-931.	2.4	137
6	Increased Cholesterol Efflux Potential of Sera From ApoA-I _{Milano} Carriers and Transgenic Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1257-1262.	2.4	114
7	Sequence polymorphisms in the apolipoprotein (a) gene. Evidence for dissociation between apolipoprotein(a) size and plasma lipoprotein(a) levels Journal of Clinical Investigation, 1993, 91, 1630-1636.	8.2	111
8	Dose-Related Effects of Repeated ETC-216 (Recombinant Apolipoprotein A-IMilano/1-Palmitoyl-2-Oleoyl) Tj ETQq American College of Cardiology, 2008, 51, 1098-1103.	0 0 0 rgB ⁻ 2.8	[/Overlock 10 87
9	Apolipoprotein A-IMilano: current perspectives. Current Opinion in Lipidology, 2003, 14, 159-163.	2.7	85
10	High-Density Lipoproteins Induce Transforming Growth Factor-β2Expression in Endothelial Cells. Circulation, 2005, 111, 2805-2811.	1.6	84
11	Omega-3 fatty acid ethyl esters increase heart rate variability in patients with coronary disease. Pharmacological Research, 2002, 45, 475-478.	7.1	70
12	Hypolipidaemic and anti-atherosclerotic effects of lupin proteins in a rabbit model. British Journal of Nutrition, 2008, 100, 707-710.	2.3	61
13	Mast Cell Chymase Degrades ApoE and ApoA-II in ApoA-I–Knockout Mouse Plasma and Reduces Its Ability to Promote Cellular Cholesterol Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1475-1481.	2.4	53
14	Reference maps of mouse serum acute-phase proteins: Changes with LPS-induced inflammation and apolipoproteinâ€A-I and A-II transgenes. Proteomics, 2005, 5, 4245-4253.	2.2	53
15	Transcriptional deregulation and a missense mutation define ANKRD1 as a candidate gene for total anomalous pulmonary venous return. Human Mutation, 2008, 29, 468-474.	2.5	52
16	The Gut Microbiota Affects Host Pathophysiology as an Endocrine Organ: A Focus on Cardiovascular Disease. Nutrients, 2020, 12, 79.	4.1	52
17	Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. British Journal of Pharmacology, 2006, 149, 909-919.	5.4	50
18	Human Apolipoproteins A-I and A-II in Cell Cholesterol Efflux. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1417-1423.	2.4	45

#	Article	IF	CITATIONS
19	Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. European Journal of Clinical Investigation, 1991, 21, 384-388.	3.4	44
20	Hypolipidemic effect of dietary pea proteins: Impact on genes regulating hepatic lipid metabolism. Molecular Nutrition and Food Research, 2010, 54, S24-30.	3.3	44
21	Apolipoprotein A-I and the molecular variant apoA-IMilano: Evaluation of the antiatherogenic effects in knock-in mouse model. Atherosclerosis, 2005, 183, 222-229.	0.8	42
22	A transgenic mouse model for the detection of cellular stress induced by toxic inorganic compounds. Nature Biotechnology, 1997, 15, 1392-1397.	17.5	41
23	Effect of Dietary Components from Antarctic Krill on Atherosclerosis in apoEâ€Deficient Mice. Molecular Nutrition and Food Research, 2017, 61, 1700098.	3.3	40
24	A Salmon Protein Hydrolysate Exerts Lipid-Independent Anti-Atherosclerotic Activity in ApoE-Deficient Mice. PLoS ONE, 2014, 9, e97598.	2.5	40
25	Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. Atherosclerosis, 2001, 156, 277-287.	0.8	39
26	Mechanisms of high-density lipoprotein reduction after probucol treatment: Changes in plasma cholesterol esterification/transfer and lipase-activities. Metabolism: Clinical and Experimental, 1993, 42, 229-235.	3.4	37
27	Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoEâ²'/â²' mice. Scientific Reports, 2017, 7, 44503.	3.3	37
28	Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction. Marine Drugs, 2016, 14, 113.	4.6	36
29	Targeted Replacement of Mouse Apolipoprotein A-I with Human ApoA-I or the Mutant ApoA-IMilano. Journal of Biological Chemistry, 2003, 278, 4740-4746.	3.4	30
30	Cholesterol-lowering effect of dietary Lupinus angustifolius proteins in adult rats through regulation of genes involved in cholesterol homeostasis. Food Chemistry, 2012, 132, 1475-1479.	8.2	29
31	Effect of the combinations between pea proteins and soluble fibres on cholesterolaemia and cholesterol metabolism in rats. British Journal of Nutrition, 2013, 110, 1394-1401.	2.3	28
32	Effects of Vegetable Proteins on Hypercholesterolemia and Gut Microbiota Modulation. Nutrients, 2018, 10, 1249.	4.1	26
33	Soy proteins reduce progression of a focal lesion and lipoprotein oxidiability in rabbits fed a cholesterol-rich diet. Atherosclerosis, 2003, 171, 163-170.	0.8	25
34	Lipid phosphate phosphatase 3 in vascular pathophysiology. Atherosclerosis, 2018, 271, 156-165.	0.8	25
35	Recombinant apolipoprotein A-I[Formula: See Text]: a novel agent for the induction of regression of atherosclerotic plaques. Annals of Medicine, 2003, 35, 267-273.	3.8	24
36	High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides. Circulation Journal, 2015, 79, 2523-2528.	1.6	23

#	Article	IF	CITATIONS
37	Acute effects of high-density lipoproteins: biochemical basis and clinical findings. Current Opinion in Cardiology, 2008, 23, 379-385.	1.8	22
38	Intracellular ANKRD1 protein levels are regulated by 26S proteasomeâ€mediated degradation. FEBS Letters, 2009, 583, 2486-2492.	2.8	22
39	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 87-93.	3.8	22
40	Rosuvastatin does not affect human apolipoprotein A-I expression in genetically modified mice: a clue to the disputed effect of statins on HDL. British Journal of Pharmacology, 2011, 164, 1460-1468.	5.4	22
41	L-homoarginine administration reduces neointimal hyperplasia in balloon-injured rat carotids. Thrombosis and Haemostasis, 2016, 116, 400-402.	3.4	22
42	Evaluation of a soft atherosclerotic lesion in the rabbit aorta by an invasive IVUS method versus a non-invasive MRI technology. Atherosclerosis, 2004, 174, 25-33.	0.8	21
43	Topiramate protects apoE-deficient mice from kidney damage without affecting plasma lipids. Pharmacological Research, 2019, 141, 189-200.	7.1	21
44	Fenretinide treatment accelerates atherosclerosis development in apoEâ€deficient mice in spite of beneficial metabolic effects. British Journal of Pharmacology, 2020, 177, 328-345.	5.4	21
45	HDL Therapy for the Treatment of Cardiovascular Diseases. Current Vascular Pharmacology, 2009, 7, 550-556.	1.7	20
46	Elevated triglycerides and low HDL cholesterol in transgenic mice expressing human apolipoprotein A-IMilano. Atherosclerosis, 1998, 136, 139-146.	0.8	19
47	Lupin <i>(Lupinus albus)</i> Protein Isolate (L-ISO) Has Adequate Nutritional Value and Reduces Large Intestinal Weight in Rats after Restricted and ad libitum Feeding. Annals of Nutrition and Metabolism, 2006, 50, 528-537.	1.9	18
48	Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. Thrombosis and Haemostasis, 2012, 108, 1246-1248.	3.4	18
49	Transgenic mice expressing a human apolipoprotein[a] allele. Journal of Lipid Research, 1999, 40, 994-1006.	4.2	18
50	Reduced biliary sterol output with no change in total faecal excretion in mice expressing a human apolipoprotein Aâ€I variant. Liver International, 2012, 32, 1363-1371.	3.9	17
51	High-density lipoprotein deficiency in genetically modified mice deeply affects skin morphology: A structural and ultrastructural study. Experimental Cell Research, 2015, 338, 105-112.	2.6	17
52	An Immunomodulating Fatty Acid Analogue Targeting Mitochondria Exerts Anti-Atherosclerotic Effect beyond Plasma Cholesterol-Lowering Activity in apoE-/- Mice. PLoS ONE, 2013, 8, e81963.	2.5	17
53	Magnetic Resonance Imaging Visualization of Vulnerable Atherosclerotic Plaques at the Brachiocephalic Artery of Apolipoprotein E Knockout Mice by the Blood-Pool Contrast Agent B22956/1. Molecular Imaging, 2014, 13, 7290.2014.00012.	1.4	16
54	A simple method for the characterization and quantification of soy isoflavone metabolites in the serum of MMTV-Neu mice using high-performance liquid chromatography/electrospray ionization mass spectrometry with multiple reaction monitoring. Rapid Communications in Mass Spectrometry, 2005, 19, 153-161.	1.5	15

#	Article	IF	CITATIONS
55	Prevalence of classical CD14++/CD16 â^' but not of intermediate CD14++/CD16 + monocytes in hypoalphalipoproteinemia. International Journal of Cardiology, 2013, 168, 2886-2889.	1.7	15
56	Myocardial overexpression of ANKRD1 causes sinus venosus defects and progressive diastolic dysfunction. Cardiovascular Research, 2020, 116, 1458-1472.	3.8	15
57	Aortic Gene Expression Profiles Show How ApoA-I Levels Modulate Inflammation, Lysosomal Activity, and Sphingolipid Metabolism in Murine Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 651-667.	2.4	12
58	Infusions of Large Synthetic HDL Containing Trimeric apoA-I Stabilize Atherosclerotic Plaques in Hypercholesterolemic Rabbits. Canadian Journal of Cardiology, 2019, 35, 1400-1408.	1.7	11
59	Fatâ€Shaped Microbiota Affects Lipid Metabolism, Liver Steatosis, and Intestinal Homeostasis in Mice Fed a Lowâ€Protein Diet. Molecular Nutrition and Food Research, 2020, 64, e1900835.	3.3	11
60	Use of recombinant apolipoproteins in vascular diseases: the case of apoA-I. Current Opinion in Investigational Drugs, 2002, 3, 420-6.	2.3	10
61	Reduced mammary tumor progression in a transgenic mouse model fed an isoflavoneâ€poor soy protein concentrate. Molecular Nutrition and Food Research, 2008, 52, 1121-1129.	3.3	9
62	In vitro activity of probucol on cholesteryl ester transport. Lipids and Lipid Metabolism, 1990, 1045, 302-304.	2.6	8
63	Predictability of low-density lipoprotein levels during apheretic treatment of hypercholesterolemia. European Journal of Clinical Investigation, 1991, 21, 209-214.	3.4	8
64	Activity profile of gemfibrozil on the major plasma lipoprotein parameters. European Journal of Epidemiology, 1992, 8, 120-124.	5.7	7
65	reString: an open-source Python software to perform automatic functional enrichment retrieval, results aggregation and data visualization. Scientific Reports, 2021, 11, 23458.	3.3	6
66	Lack of ApoA-I in ApoEKO Mice Causes Skin Xanthomas, Worsening of Inflammation, and Increased Coronary Atherosclerosis in the Absence of Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 839-856.	2.4	6
67	Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis. Clinica Chimica Acta, 1995, 240, 75-81.	1.1	5
68	liputils: a Python module to manage individual fatty acid moieties from complex lipids. Scientific Reports, 2020, 10, 13368.	3.3	3
69	Effects of probucol on the high density lipoprotein system in hypercholesterolaemic patients. Pharmacological Research, 1989, 21, 113-114.	7.1	2
70	Management of lipoprotein-X accumulation in severe cholestasis by semi-selective LDL-apheresis. American Journal of Medicine, 1991, 90, 633-638.	1.5	1
71	Mechanisms of hdl reduction after probucol: Changes in cholesterol esterification/transfer and lipase activities. Pharmacological Research, 1992, 26, 30.	7.1	1
72	Apo(a) Expression in Transgenic Micea. Annals of the New York Academy of Sciences, 1994, 714, 231-236.	3.8	0

#	Article	IF	CITATIONS
73	Th-P15:199 Modulation of pentraxin 3 expression in endothelial cells: Role of HDL. Atherosclerosis Supplements, 2006, 7, 537.	1.2	0
74	Tu-W23:7 Effect of high cholesterol diet on cholesterol and bile acid metabolism in A-IM and A-I transgenic mice. Atherosclerosis Supplements, 2006, 7, 167.	1.2	0
75	We-P14:483 Evaluation of nutritional and biological properties of a lupin protein isolate in Sprague-Dawley rats. Atherosclerosis Supplements, 2006, 7, 453-454.	1.2	0
76	Rupatadine treatment is associated to atherosclerosis worsening and altered T lymphocyte recruitment. Thrombosis and Haemostasis, 2021, 0, .	3.4	0